"From the presentations we saw at JPM this year, it was clear that infrastructure to support AI systems...continues to be a work in progress."
To Duffy, there seemed to be a consensus that a "medication alone" approach will not be sufficient when it comes to GLP-1s.
[
add
]
[
|
|
...
]